Furthermore, more randomized or controlled studies with more clinical phenotypes and more combination treatment options are required to evaluate the effects of HCQ treatment on lung disease caused by NKX2-1 pathogenic variants. This evidence concerns the gene NKX2-1 and lung disorder.